Characteristics of 2,439 men initially diagnosed with nonmetastatic prostate cancer in the HPFS and the PHS
| HPFS | PHS | Total | |
|---|---|---|---|
| Number of participants | 1,206 | 1,233 | 2,439 |
| Date of diagnosis (median, IQR) | 1999 (1997, 2002) | 1995 (1991, 1999) | 1998 (1994, 2001) |
| Age at diagnosis, y (mean ± SD) | 70 ± 7 | 70 ± 7 | 70 ± 7 |
| Smoking status at blood draw (%) | |||
| Never | 50 | 48 | 49 |
| Former, quit ≥10 y | 38 | 36 | 37 |
| Former, quit <10 y | 8 | 11 | 10 |
| Current | 3 | 4 | 4 |
| Missing | 1 | 0 | 0 |
| BMI at blood draw (%) | |||
| <25 kg/m2 | 50 | 59 | 55 |
| 25–29.9 kg/m2 | 41 | 39 | 40 |
| ≥30 kg/m2 | 8 | 3 | 5 |
| Gleason sum at diagnosis (%) | |||
| <7 | 52 | 59 | 56 |
| 7 | 35 | 23 | 29 |
| ≥8 | 11 | 11 | 11 |
| Missing | 2 | 7 | 5 |
| Clinical stage T3, % | 2 | 6 | 4 |
| PSA at diagnosis, ng/mL (median, IQR) | 7 (5, 10) | 7 (5, 12) | 7 (5, 11) |
| α-tocopherol, mg/L (median, IQR) | 12.3 (9.0, 16.5) | 11.1 (9.2, 13.7) | 11.4 (9.1, 14.6) |
| γ-tocopherol, mg/L (median, IQR) | 1.5 (0.9, 2.3) | 1.9 (1.4, 2.5) | 1.8 (1.2, 2.4) |
| Lycopene, ng/mL (median, IQR) | 396 (291, 539) | 313 (210, 474) | 352 (239, 507) |
| Time from blood draw to diagnosis, y (median, IQR) | 6 (3, 8) | 13 (9, 17) | 8 (5, 13) |
| Metastases or deaths due to prostate cancer, N (%) | 84 (7) | 139 (11) | 223 (9) |